Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
600 participants
INTERVENTIONAL
2014-03-31
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There are significant variations from one population to another. Clinical manifestations of schizophrenia (symptoms, evolution, severity of disability) are highly variable. This variability, both epidemiological and clinical, is due to genetic and environmental factors.
Environmental factors may be either risk factors or modifying factors (changing clinical presentation but do not alter the risk of disease) for schizophrenia.
Environmental risk factors have been identified (eg: urbanity, cannabis, migration), but the investigators don't know neither the components directly responsible, nor the mechanisms by which they increase the risk of schizophrenia.
To date, there is no study has systematically evaluated the role of environmental modifying factors in schizophrenia.
Environmental factors may be individual, unique to each person (eg cannabis, migration.), or population-based (eg ethnic density, socio-economic difficulties.) The identification/ identifying of environmental risk factors or modifiers, both individual and population, may have theoretical implications (understanding of etiopathogenic mechanisms) and practical (implementation of preventive measures). The potential effectiveness of preventive measures is even greater than the risk attributable to certain environmental factors is important.
Most studies on environmental factors in schizophrenia were conducted in Anglo-Saxon countries and northern Europe, but no study of these risk factors has been conducted in France.
There are important differences environment based on study populations, these results are not generalizable to other countries, including France.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with schizophrenia
Clinical and environmental evaluation
For schizophrenic's patients, specific assessment will be perform
Relatives
Clinical and environmental evaluation
For schizophrenic's patients, specific assessment will be perform
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical and environmental evaluation
For schizophrenic's patients, specific assessment will be perform
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* Somatic state / condition and level of understanding (language, intellectual level) compatible with the data collection (interview, self-administered questionnaires)
Patients
* Diagnosis of schizophrenia according to DSM-IV criteria
* Living in catchment areas
All subjects
* Not affiliated to the social security scheme
* inability to provide informed consent
* Decompensated schizophrenic underway
Relatives
* Protective Measures (tutor, curator)
Exclusion Criteria
* The diagnosis of psychotic disorder is not confirmed by the synthesis of all clinical data
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut national d'étude démographique (INED)
UNKNOWN
CPN (INSERM U894) CH Sainte-Anne - Paris
UNKNOWN
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Fondation FondaMental
OTHER
University Hospital, Clermont-Ferrand
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franck Schürhoff, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Pierre-Michel Llorca, MD PhD
Role: PRINCIPAL_INVESTIGATOR
CHU de Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henri Mondor Hospital
Créteil, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P100134
Identifier Type: -
Identifier Source: org_study_id